RNA Therapy Enhanced Fat Loss in Mice Study

Researchers combined a new RNA therapy with semaglutide to improve weight loss while better preserving lean muscle mass.

Updated on Sept. 21, 2026 in Weight Loss

Isometric editorial illustration of a single laboratory glass vial in a clean pipette rack, representing medical research progress. — Researchers at Northwestern University have developed an RNA-based therapy that, combined with semaglutide, increases fat loss and preserves lean muscle in mouse studies. AI Illustration. Upload story photo >

Live Poll

Should future weight-loss medications prioritize preserving muscle mass over total weight reduction?

Scientists at Northwestern Universitys Feinberg School of Medicine developed an RNA-based therapy that, when paired with semaglutide, significantly boosted fat reduction in mice. The treatment also proved more effective at preserving lean muscle mass than using the popular weight loss drug alone.

Why it matters

While GLP-1 medications like semaglutide are effective for weight loss, they often cause patients to lose significant lean muscle mass alongside body fat. This new dual-therapy approach aims to mitigate that side effect by specifically targeting energy-burning fat cells.

Mice treated with the combined therapy ended with 4 g of body fat, compared to 8 g in the group receiving semaglutide alone. This combination therapy also resulted in a 5.5% reduction in lean mass, significantly better than the 10% loss observed in the semaglutide-only group.

The players

Feinberg School of Medicine, Northwestern University

This is a prominent medical research institution based in the United States that conducted the study on the new RNA therapy.

The details

The experimental therapy utilizes short RNA strands to inhibit the ZFP423 gene, which prompts the body to convert white fat into energy-burning beige fat. Beyond fat loss and muscle preservation, the treatment also demonstrated an improvement in glucose tolerance during the study.

September 21, 2026: The study findings were published in the Proceedings of the National Academy of Sciences.

The Big Picture

This research follows the rigorous peer-review standards established by the Proceedings of the National Academy of Sciences. The publication of these findings provides a standardized platform for these new results to influence the broader trajectory of metabolic disorder research.

This research suggests a future path where weight loss medications could become more effective while reducing the common side effect of muscle loss. If these findings translate to humans, future patients could maintain better physical strength and metabolic health during treatment.

The takeaway

While this study offers promising results for muscle preservation, it remains limited to mouse models and has not yet been tested in humans. Future human trials will be necessary to determine if targeting the ZFP423 gene provides similar benefits for patients.